Transgene Biotek Ltd: Board Approves Unaudited Financial Results
Transgene Biotek Ltd announced that its Board of Directors, in a meeting held on November 13, 2026, approved the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The board also took on record the limited review reports for these results. Additionally, the company approved the notice for its 36th Annual General Meeting (AGM) for FY 2025-26, scheduled for December 30, 2026. The Directors' Report for FY 2025-26 was also approved. The register of members and share transfer books will be closed from December 24 to December 30, 2026. Mrs. Geeta Servani was appointed as the scrutinizer for the e-voting process. The re-appointment of Dr. K. Koteswara Rao as Chairman and Managing Director for one year was approved, subject to shareholder approval.
Key Highlights
- Board approved unaudited financial results for Q2 FY27.
- Limited review reports for the results were taken on record.
- 36th AGM scheduled for December 30, 2026.
- Chairman and MD re-appointment approved, pending shareholder nod.
- Register of members to close for AGM from Dec 24-30, 2026.
Price Impact
More from TRABI